A medical AI company dedicated to advancing stroke care, PurpleAI Inc. has closed a $2.5M Series A funding round. The capital infusion comes from Murex Partners, Taurus Partners, and Korea Credit Guarantee Fund, backing the company's mission to enhance stroke detection and predictive clinical intelligence.
PurpleAI, which became an independent entity in October 2024 after operating within SK Group since 2019, develops clinically integrated AI solutions. Its Hyper Insight™ and Medical Insight+™ portfolios provide advanced neuroimaging analysis, while its upcoming StrokeShieldAI platform aims to anticipate and monitor high-risk complications following initial stroke treatment.
















